کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
9016307 | 1128087 | 2005 | 11 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
The influence of Serotonin Transporter Promoter Polymorphism (SERTPR) and other polymorphisms of the serotonin pathway on the efficacy of antidepressant treatments
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
TphN-ethyl-3,4-methylenedioxyamphetamineserotonin transporter promoter polymorphismMAOAMDEMAOIGNB35HTVASVNTRAADCaffective disorders - اختلالات عاطفیDepression - افسردگیvariable number tandem repeat - تکرار تعداد متغیرAntidepressant drug - داروهای ضد افسردگیSERT - سختSerotonin - سروتونینserotonin transporter - سروتونین حمل کنندهPharmacogenetics - فارماکوژنتیکSleep deprivation - محرومیت از خوابvisual analogue scale - مقیاس آنالوگ بصریHamilton Rating Scale for Depression - مقیاس رتبه بندی همیلتون برای افسردگیSelective serotonin reuptake inhibitor - مهار کننده بازجذب سروتونین انتخابیMAO inhibitors - مهار کننده های MAOSSRI - مهارکنندههای بازجذب سروتونینHAMD - همدن
موضوعات مرتبط
علوم زیستی و بیوفناوری
علم عصب شناسی
روانپزشکی بیولوژیکی
پیش نمایش صفحه اول مقاله
چکیده انگلیسی
The definition of a genetic liability profile for specific antidepressant treatment will soon be available offering considerable help in early detection of effective therapy in affective disorders. The search for genetic factors predisposing to drug response or side-effects in affective disorders started only in the last few years. The efficacy of antidepressant action was associated with several polymorphisms, located on coding genes of proteins thought to be involved in the different mechanisms of action of antidepressant treatments. Among these, gene variants in sequences of serotonin pathway proteins were candidate, both for the well known evidence of its involvement in the development of depressive symptomathology and for the wide-world use of selective serotonin reuptake inhibitors as first choice treatment of depression. A polymorphism in the promoter region of the serotonin transporter (SERTPR) was independently associated with efficacy for a range of treatments, other polymorphism located on the tryptophan hydroxylase gene, 5-HT2a receptor and G-protein beta 3 showed some association, while other candidate genes were not associated with treatment efficacy. Possible liability genes controlling at least to some extent both acute and long-term treatment were identified, and the further objective is to identify other candidate genes in order to define individualized treatments according to genetic profile in a future. The present paper reviews the pharmacogenetic studies published to date, focusing the attention on the serotonergic pathway.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Progress in Neuro-Psychopharmacology and Biological Psychiatry - Volume 29, Issue 6, July 2005, Pages 1074-1084
Journal: Progress in Neuro-Psychopharmacology and Biological Psychiatry - Volume 29, Issue 6, July 2005, Pages 1074-1084
نویسندگان
Alessandro Serretti, Francesco Benedetti, Raffaella Zanardi, Enrico Smeraldi,